HCM
What one share of HutchMED (China) LIMITED holds
Pharmaceutical Preparations
We are a global commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies and immunotherapies for the treatment of patients with cancer and immunological diseases.
HutchMED (China) LIMITED’s numbers from its SEC filings, divided by its shares. Results cover the latest fiscal year to 2025-12-31; the balance sheet is as of 2025-12-31.
| Sales | $3.14 |
|---|---|
| Profit | $2.62 |
| Capex (buildings and equipment) | $0.08 |
| Free cash flow | −$0.45 |
| Cash and investments | $0.41 |
| Debt | $0.68 |
| Book value | $7.10 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2014 | $0.83 | −$0.31 | $0.04 | $0.04 | — | $0.54 |
| 2015 | $1.63 | −$0.32 | $0.03 | −$0.12 | — | $0.76 |
| 2016 | $1.80 | $0.10 | $0.04 | −$0.12 | — | $1.52 |
| 2017 | $1.95 | −$0.22 | $0.04 | −$0.11 | — | $3.47 |
| 2018 | $1.61 | −$0.56 | $0.05 | −$0.29 | — | $2.92 |
| 2019 | $1.54 | −$0.80 | $0.06 | −$0.67 | — | $2.16 |
| 2020 | $1.63 | −$0.90 | $0.06 | −$0.50 | — | $3.33 |
| 2021 | $2.25 | −$1.23 | $0.10 | −$1.39 | — | $5.71 |
| 2022 | $2.52 | −$2.13 | $0.22 | −$1.80 | — | $3.53 |
| 2023 | $4.82 | $0.59 | $0.19 | $1.07 | — | $4.19 |
| 2024 | $3.61 | $0.22 | $0.10 | −$0.10 | — | $4.36 |
| 2025 | $3.14 | $2.62 | $0.08 | −$0.45 | — | $7.10 |